Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 25 results.
User Information
Export Records
  1. 1.   Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
  2. Takebe, Naoko; Naqash, Abdul Rafeh; Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Do, Khanh; Bruns, Ashley; Juwara,Lamin; Zlott, Jennifer; Rubinstein, Larry; Piekarz, Richard; Sharon, Elad; Streicher, Howard; Mittra, Arjun; Miller, Sarah B.; Ji,Jay; Wilsker,Deborah; Kinders,Robert; Parchment,Ralph; Chen,Li; Chang,Ting-Chia; Das,Biswajit; Mugundu, Ganesh; Doroshow, James H.; Chen, Alice P.
  3. CLINICAL CANCER RESEARCH. 2021, Apr 16; 27(14): 3834-3844.
  1. 2.   Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model
  2. Yamamoto, Jun; Murata, Takuya; Sugisawa, Norihiko; Higuchi, Takashi; Tashiro, Yoshihiko; Nishino, Hiroto; Inubushi, Sachiko; Sun, Y U; Lim, Hyein; Miyake, Kentaro; Shimoya, Koichiro; Nomura, Tsunehisa; Kurebayashi, Junichi; Tanino, Hirokazu; Hozumi, Chihiro; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Anticancer research. 2020, May; 40(5): 2475-2479.
  1. 3.   A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
  2. Igarashi, Kentaro; Kawaguchi, Kei; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Higuchi, Takashi; Taniguchi, Yuta; Yonezawa, Hirotaka; Araki, Yoshihiro; Morinaga, Sei; Misra,Sweta; Nelson, Scott D.; Dry, Sarah M.; Li, Yunfeng; Odani, Akira; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. Cancer genomics & proteomics. 2020, May-Jun; 17(3): 217-223.
  1. 4.   PPAR gamma Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model
  2. Higuchi, Takashi; Yamamoto, Jun; Sugisawa, Norihiko; Tashiro, Yoshihiko; Nishino, Hiroto; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Cancer genomics & proteomics. 2020, Jan-Feb; 17(1): 35-40.
  1. 5.   Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients
  2. Yin, J.; Yan, X. D.; Yao, X.; Zhang, Y. L.; Shan, Y.; Mao, N.; Yang, Y. L.; Pan, L. Y.
  3. Journal of Cellular and Molecular Medicine. 2012, Feb; 16(2): 337-348.
  1. 6.   Selective Modulation of DNA Polymerase Activity by Fixed-Conformation Nucleoside Analogues
  2. Eoff, R. L.; McGrath, C. E.; Maddukuri, L.; Salamanca-Pinzon, S. G.; Marquez, V. E.; Marnett, L. J.; Guengerich, F. P.; Egli, M.
  3. Angewandte Chemie-International Edition. 2010, Oct 4; 49(41): 7481-7485.
  1. 7.   Transcriptional up-regulation of SOD1 by CEBPD: A potential target for cisplatin resistant human urothelial carcinoma cells
  2. Hour, T. C.; Lai, Y. L.; Kuan, C. I.; Chou, C. K.; Wang, J. M.; Tu, H. Y.; Hu, H. T.; Lin, C. S.; Wu, W. J.; Pu, Y. S.; Sterneck, E.; Huang, A. M.
  3. Biochemical Pharmacology. 2010, Aug; 80(3): 325-334.
  1. 8.   Increased Expression of Annexin A3 Is a Mechanism of Platinum Resistance in Ovarian Cancer
  2. Yan, X. D.; Yin, J.; Yao, H. Y.; Mao, N.; Yang, Y. L.; Pan, L. Y.
  3. Cancer Research. 2010, Feb; 70(4): 1616-1624.
  1. 9.   Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: Production of hepatocellular carcinoma at clinically relevant doses
  2. Waalkes, M. P.; Liu, J.; Kasprzak, K. S.; Diwan, B. A.
  3. International Journal of Cancer. 2006, JUL 1; 119(1): 28-32.
  1. 10.   PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity
  2. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X. H.; Keefer, L. K.
  3. Journal of Medicinal Chemistry. 2006, FEB 9; 49(3): 1157-1164.
  1. 11.   Role of GADD34 in modulation of cisplatin cytotoxicity
  2. Fishel, M. L.; Rabik, C. A.; Bleibel, W. K.; Li, X. M.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2006, JAN 12; 71(3): 239-247.
  1. 12.   Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: Potential role in skin co-carcinogenesis
  2. Pi, J. B.; He, Y. Y.; Bortner, C.; Huang, J. L.; Liu, J.; Zhou, T.; Qu, W.; North, S. L.; Kasprzak, K. S.; Diwan, B. A.; Chignell, C. F.; Waalkes, M. P.
  3. International Journal of Cancer. 2005, AUG 10; 116(1): 20-26.
  1. 13.   Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O-6-benzylguanine
  2. Fishel, M. L.; Ganicsik, M. P.; Delaney, S. M.; Zuhowski, E. G.; Maher, V. M.; Karrison, T.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2005, APR; 55(4): 333-342.
  1. 14.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 15.   Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C
  2. Li, F.; Wang, F.; Haraldson, K.; Protopopov, A.; Duh, F. M.; Geil, L.; Kuzmin, I.; Minna, J. D.; Stanbridge, E.; Braga, E.; Kashuba, V. I.; Klein, G.; Lerman, M. I.; Zabarovsky, E. R.
  3. Cancer Research. 2004, SEP 15; 64(18): 6438-6443.
  1. 16.   Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
  2. Liu, J.; Li, C. X.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Molecular Cancer Therapeutics. 2004 3(6): 709-714.
  1. 17.   Enhancement of platinum-induced cytotoxicity by O-6- Benzylguanine
  2. Fishel, M. L.; Delaney, S. M.; Friesen, L. D.; Hansen, R. J.; Zuhowski, E. G.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2003 2(7): 633-640.
  1. 18.   Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice
  2. Papadopoulou, M. V.; Ji, M.; Ji, X. H.; Bloomer, W. D.; Hollingshead, M. G.
  3. Cancer Chemotherapy and Pharmacology. 2002 50(6): 501-508.
  1. 19.   DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program
  2. Xu, Z. Y.; Chen, Z. P.; Malapetsa, A.; Alaoui-Jamali, M.; Bergeron, J.; Monks, A.; Myers, T. G.; Mohr, G.; Sausville, E. A.; Scudiero, D. A.; Aloyz, R.; Panasci, L. C.
  3. Anti-Cancer Drugs. 2002 13(5): 511-519.
  1. 20.   Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic
  2. Liu, J.; Chen, H.; Miller, D. S.; Saavedra, J. E.; Keefer, L. K.; Johnson, D. R.; Klaassen, C. D.; Waalkes, M. P.
  3. Molecular Pharmacology. 2001 60(2): 302-309.
  1. 21.   Chromium mapping in male mice reproductive glands exposed to CrCl3 using proton and X-ray synchrotron radiation microbeams
  2. Ortega, R.; Deves, G.; Bonnin-Mosbah, M.; Salome, M.; Susini, J.; Anderson, L. M.; Kasprzak, K. S.
  3. Nuclear Instruments & Methods in Physics Research Section B- Beam Interactions with Materials and Atoms. 2001 181: 485-488.
  1. 22.   UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
  2. Monks, A.; Harris, E. D.; Vaigro-Wolff, A.; Hose, C. D.; Connelly, J. W.; Sausville, E. A.
  3. Investigational New Drugs. 2000 18(2): 95-107.
  1. 23.   Preclinical Evaluation of 9-Chloro-2-Methylellipticinium Acetate Alone and in Combination With Conventional Anticancer Drugs For the Treatment of Human Brain Tumor Xenografts
  2. Arguello, F.; Alexander, M. A.; Greene, J. F.; Stinson, S. F.; Jorden, J. L.; Smith, E. M.; Kalavar, N. T.; Alvord, W. G.; Klabansky, R. L.; Sausville, E. A.
  3. Journal of Cancer Research and Clinical Oncology. 1998 124(1): 19-26.
  1. 24.   A Phase Ii Study of Carboplatin, Cisplatin, Interferon-Alpha, and Tamoxifen For Patients With Metastatic Melanoma
  2. Gause, B. L.; Sharfman, W. H.; Janik, J. E.; Curti, B. D.; Steis, R. G.; Urba, W. J.; Smith, J. W.; Alvord, W. G.; Longo, S. L.
  3. Cancer Investigation. 1998 16(6): 374-380.
  1. 25.   Transplacental Cisplatin Exposure Induces Persistent Fetal Mitochondrial and Genomic Dna Damage in Patas Monkeys
  2. Giurgiovich, A. J.; Anderson, L. M.; Jones, A. B.; Dove, L. F.; Moskal, T. J.; Rice, J. M.; Olivero, O. A.; Poirier, M. C.
  3. Reproductive Toxicology. 1997 11(1): 95-100.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel